Mount Sinai Hospital-The Donald H. Ruttenberg Cancer Treatment Center

New York, New York 10011

0 studies enrolling now · 1 studies all time

What they study most

Multiple Myeloma, Relapsed/Refractory

Studies at this site

• A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM) — Completed